Previous Close | 5.14 |
Open | 5.17 |
Bid | 5.06 x 3000 |
Ask | 5.07 x 4000 |
Day's Range | 5.05 - 5.17 |
52 Week Range | 4.37 - 7.70 |
Volume | 806,555 |
Avg. Volume | 1,568,507 |
Market Cap | 783.457M |
Beta (3Y Monthly) | 1.68 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.76 |
Earnings Date | Feb 10, 2020 - Feb 14, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.38 |
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -26.67% and -21.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif., Nov. 07, 2019 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company’) today announced financial results for its third quarter ended.
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
MENLO PARK, Calif., Oct. 10, 2019 -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 11.11% and 10.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
Bad news on several different fronts held these stocks back.
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved.
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
We at Insider Monkey have gone over 738 13F filings that hedge funds and famous value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Pacific Biosciences of California, Inc. (NASDAQ:PACB). Pacific […]
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
In early November the companies said Illumina, the San Diego provider of DNA-sequencing technologies for research and clinical use, agreed to pay $8 a share for its Menlo Park, California, rival. The deal's enterprise value is $1.2 billion. Early in Wall Street trading, Pacific Biosciences shares fell 3% to $6.48.
MENLO PARK, Calif., June 13, 2019 -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.